(NasdaqGM:WRD),(HKSE: 0800.HK),(HKSE: 0800-HK),(NASDAQ:^HXC), NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) — WeRide Inc. (“WeRide” or the “Company”) (Nasdaq: WRD, HKEX:0800), a global leader in autonomous driving technology, today announced its unaudited financial results for the three months ended September 30, 2025. Financial and Operational Highlights Total revenue grew 144.3% year-over-year (YoY) to RMB171.0 million (US$24.0 […]

DUBAI, United Arab Emirates, Nov. 24, 2025 (GLOBE NEWSWIRE) — Mutuum Finance (MUTM) is entering one of its most defining moments, with Phase 6 now 90% sold out as the project moves closer to its Q4 2025 V1 protocol launch. Interest in the presale has accelerated as the team continues to release updates on development,

(TSX-V:RKV),(Boerse Frankfurt – Freiverkehr:7JO0), VANCOUVER, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, today announced impressive results from its AI-enabled ATR program at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting which took place November

(TSX-V:WHN),(TSX-V:WHN.V), VANCOUVER, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) — Westhaven Gold Corp. (TSX-V: WHN) (“Westhaven” or the “Company“) is pleased to announce the completion of an upsized summer drilling program as part of the Company's ongoing evaluation of its 100%-owned Shovelnose Gold Project (“Shovelnose“) located within southern British Columbia's Spences Bridge Gold Belt (“SBGB“).

(NASDAQ:GNTA), MILAN, Italy and NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) — Genenta Science (Nasdaq: GNTA), a clinical-stage biotechnology company developing a cell-based platform for targeted delivery of therapeutic payloads in oncology, today announced an update from its ongoing TEM-GBM study in newly diagnosed glioblastoma multiforme (GBM) patients with an unmethylated MGMT (uMGMT) gene promoter.

Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial Company Announces Approximately $30 Million in Cash and Short-Term Investments Following Its October 27th Registered Direct Offering GlobeNewswire November 24, 2025 MILAN, Italy and NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) — Genenta Science (Nasdaq: GNTA), a clinical-stage biotechnology company developing a

Global Expansion Accelerates: Landmark UAE Driverless Robotaxi Commercial Permit, Autonomous Vehicles Licensed in Eight Countries, Record YoY Revenue Growth of 144.3% WeRide Announces Unaudited Financial Results for Q3 2025 GlobeNewswire November 24, 2025 NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) — WeRide Inc. (“WeRide” or the “Company”) (Nasdaq: WRD, HKEX:0800), a global leader in autonomous

Mutuum Finance (MUTM) Phase 6 Is 90% Sold Out Ahead of Its Q4 2025 V1 Protocol Launch GlobeNewswire November 24, 2025 DUBAI, United Arab Emirates, Nov. 24, 2025 (GLOBE NEWSWIRE) — Mutuum Finance (MUTM) is entering one of its most defining moments, with Phase 6 now 90% sold out as the project moves closer to

Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting Variational AI's Enki(TM) generative AI platform designed novel ATR/mTOR dual inhibitors with brain penetrance and activity in PTEN-deficient tumor models GlobeNewswire November 24, 2025 VANCOUVER, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc.

Westhaven Advances Exploration and Development Programs at Shovelnose Gold Project, Southern British Columbia South Zone Resource & New Exploration Models Confirmed GlobeNewswire November 24, 2025 VANCOUVER, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) — Westhaven Gold Corp. (TSX-V: WHN) (“Westhaven” or the “Company“) is pleased to announce the completion of an upsized summer drilling program